Swiss dental company vVARDIS prices its US IPO at $18 a share, below its expected $21 to $24 range
The maker of the drill-free Curodont cavity treatment sold 9,722,223 shares, more than the 8,333,334 it had offered, and says it is now listed on the NYSE.
By Startups Desk ·
The short version
- vVARDIS priced 9,722,223 Class A shares at $18.00, its website says. Its November 12 prospectus had offered 8,333,334 shares at an expected $21.00 to $24.00.
- By our arithmetic, the final terms come to about $175.0 million before fees, the same as the original share count at the bottom of the range.
- The prospectus reports net revenue of $30.2 million and a net loss of $56.4 million for 2025, and total loans of $84.2 million at June 30, 2026.
- Its founders are to hold a separate class of voting shares; the prospectus put their voting power at 87.6%, based on the smaller share count offered then.
vVARDIS Holding AG, a company based in Zug, Switzerland, that sells a treatment for early tooth decay applied without drilling, priced its US initial public offering at $18.00 per Class A ordinary share, according to an announcement its press-release page lists under November 13, 2026. It sold 9,722,223 shares. As late as November 12, in the second amendment to its registration statement, the company was still offering 8,333,334 shares at an expected $21.00 to $24.00 each. The SEC's EDGAR system records the registration statement as effective from 5:30 p.m. on November 12, and the company's website now says its shares are listed on the New York Stock Exchange under the symbol VVVV.
By our calculation, the final price sits 14.3% below the bottom of that range and 20.0% below its $22.50 midpoint, while the share count rose by 1,388,889, or 16.7%. At $18.00, the 9,722,223 shares come to $175,000,014 before underwriting discounts and expenses, exactly what the original 8,333,334 shares would have raised at $21.00, the bottom of the range. These figures are our own arithmetic; the summary on the company's website gives only the share count and the price.
| November 12 prospectus | Priced, per the company | |
|---|---|---|
| Class A shares sold by the company | 8,333,334 | 9,722,223 |
| Price per share | $21.00 to $24.00 (expected) | $18.00 |
| Gross amount | $175.0 million to $200.0 million | $175.0 million |
| Underwriters' option for extra shares | Up to 1,250,000 | Not given in the summary |
The final prospectus, which would state the underwriting discount at the final price, was not on the company's EDGAR filing list when we checked it on November 14. At the $22.50 midpoint, the November 12 prospectus estimated net proceeds of about $166.2 million, for general corporate purposes. Goldman Sachs and J.P. Morgan were joint bookrunning managers.
What the company sells
Two dentists, Haley Abivardi and Goly Abivardi, founded the company in Switzerland and serve as co-chief executive officers. According to the prospectus, its Curodont products are peptide-containing formulas designed to halt early cavities and repair damaged enamel while leaving the natural tooth in place. In the United States, which accounts for the vast majority of revenue, it sells Curodont Repair Fluoride Plus. Because the product contains sodium fluoride, the FDA regulates it as an over-the-counter drug, and the prospectus states that the agency has not made any determination about its safety or efficacy. Other markets get a version called Curodont Repair.
The company estimates that, after its US launch in January 2024, its products had treated more than 3.5 million teeth by June 30, 2026, and that its flagship products had been sold to more than 20,000 of the roughly 110,000 general dental practices in the country. Its press-release page lists a December 2025 announcement naming Henry Schein as exclusive distributor of Curodont Repair Fluoride Plus across all US dental segments.
Fast sales growth, continuing losses
Net revenue rose 148.5% to $30.2 million in 2025, and 214.2% to $28.6 million in the first half of 2026, on a year earlier. In a section of preliminary results, it estimated net revenue of $47.7 million to $49.2 million for the first nine months of 2026, against $22.3 million a year earlier, with a net loss of $39.7 million to $41.3 million, close to the $40.7 million of the same period in 2025. The company says its final nine-month results may differ from these estimates, though it does not expect them to differ materially.
| Period | Net revenue | Net loss |
|---|---|---|
| Year 2025 | 30.2 | 56.4 |
| First half 2026 | 28.6 | 27.8 |
| Nine months 2025 | 22.3 | 40.7 |
| Nine months 2026 (estimate) | 47.7 to 49.2 | 39.7 to 41.3 |
The company also carries debt. Total loans stood at $84.2 million at June 30, 2026, and on its preliminary estimates the company expects cash and cash equivalents of $19.4 million at September 30, 2026. Under a credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP, it took a $35.0 million term loan in February 2025, due in 2030, and added a second tranche of $50.0 million in June 2025, for total borrowings of $85.0 million. The prospectus describes two waivers this year: one in April, after the company missed a $5.0 million ordinary-share financing requirement, and one in September, tied to the liquidation of two subsidiaries. Among its risk factors, the company says its ability to continue as a going concern may depend on raising more capital, increasing revenue and managing expenses.
Who controls the company
Immediately before the offering is completed, the prospectus says, the company's existing shares are converted into Class A ordinary shares and Class B voting rights shares, all of the latter owned by the two founders. Each share has one vote, but a Class B share's far lower par value gives it ten times the voting power of a Class A share relative to the capital invested. Based on the 8,333,334 shares offered on November 12, the prospectus put the founders' voting power at 87.6%; the final figure depends on the larger number sold. As a controlled company under NYSE rules, vVARDIS may opt for lighter governance requirements, the prospectus says.
Sources
- vVARDIS Holding AG, Amendment No. 2 to Form F-1 (preliminary prospectus dated November 12, 2026) U.S. Securities and Exchange Commission (EDGAR), November 12, 2026
- vVARDIS Holding AG, notice of effectiveness, file no. 333-299384 U.S. Securities and Exchange Commission (EDGAR), November 12, 2026
- vVARDIS Holding AG, EDGAR filing list U.S. Securities and Exchange Commission (EDGAR), November 14, 2026
- Press releases vVARDIS, November 14, 2026
- vVARDIS x New York Stock Exchange vVARDIS, November 14, 2026
Researched and drafted with AI assistance, then checked against the 5 sources above in a separate fact-check on November 14, 2026. Spotted an error? Tell us.